https://www.marketscreener.com/quote/stock/MYOVANT-SCIENCES-LTD-31698733/news/Urovant-Sciences-to-Present-Interim-Data-from-Phase-2a-Study-of-Potential-Novel-Gene-Therapy-at-2022-40055232/?utm_source=telegram&utm_medium=social&utm_campaign=share